[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Beutler D, Avoledo P, Reubi JC, Mäcke HR, Müller-Brand J, Merlo A, Kühne T: Three-year recurrence-free survival in a patient with recurrent medulloblastoma after resection, high-dose chemotherapy, and intrathecal Yttrium-90-labeled DOTA0-D-Phe1-Tyr3-octreotide radiopeptide brachytherapy. Cancer; 2005 Feb 15;103(4):869-73
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-year recurrence-free survival in a patient with recurrent medulloblastoma after resection, high-dose chemotherapy, and intrathecal Yttrium-90-labeled DOTA0-D-Phe1-Tyr3-octreotide radiopeptide brachytherapy.
  • BACKGROUND: Most medulloblastomas express high levels of somatostatin type 2 receptors (sst2).
  • The authors applied this innovative treatment option in a boy age 8 years who presented with a recurrent medulloblastoma of the cauda equina: a prognostically poor condition.
  • Targeted radiotherapy was administered to treat minimal sst2-expressing tumor remnants, which persisted despite conventional and high-dose chemotherapy and intercurrent resection of the lesion.
  • METHODS: A medulloblastoma arising from the floor of the fourth ventricle had been removed surgically; then, the patient was treated with standard adjuvant chemotherapy and craniospinal irradiation according to the prospective HIT '91 protocol.
  • Complete remission was achieved for 20 months, when a drop metastasis of the cauda equina manifested with sensorimotor lumbosacral deficits and urinary incontinence.
  • After four cycles of neoadjuvant chemotherapy (which consisted of combined ifosfamide, carboplatinum and etoposide), two cycles of high-dose chemotherapy and autologous stem cell transplantation were performed; in between, the responding residual tumor within the lumbosacral nerve fibers was microscopically removed.
  • Thereafter, an Indium-111-DOTATOC test injection indicated sst2-expressing tumor remnants within the cauda equina.
  • CONCLUSIONS: Intrathecal administration of targeted radiopeptide brachytherapy in combination with conventional and high-dose chemotherapy and surgical removal represents a promising new option to treat recurrent medulloblastoma and should be explored further.
  • [MeSH-major] Cauda Equina / pathology. Cerebellar Neoplasms / therapy. Medulloblastoma / secondary. Medulloblastoma / therapy. Octreotide / administration & dosage. Octreotide / analogs & derivatives
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Brachytherapy. Child. Disease-Free Survival. Humans. Immunohistochemistry. Injections, Spinal. Male. Radiopharmaceuticals. Receptors, Somatostatin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 American Cancer Society.
  • (PMID = 15641034.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0 / Receptors, Somatostatin; RWM8CCW8GP / Octreotide; U194AS08HZ / Edotreotide
  •  go-up   go-down


2. Dhatt S, Dhillon MS, Tripathy SK, Goyal T, Jagadeesh V: Peripheral primitive neuroectodermal tumor causing cauda equina syndrome with destruction of L5 vertebra. Indian J Orthop; 2010 Jul;44(3):339-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral primitive neuroectodermal tumor causing cauda equina syndrome with destruction of L5 vertebra.
  • A 24-year-old male patient presented with cauda equina lesion symptoms.
  • Histopathology and immunocytochemical analysis revealed it to be primitive neuroectodermal tumor.
  • Patient was given chemotherapy and radiation therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 1982 Sep;139(3):571-6 [6981325.001]
  • [Cites] J Neurooncol. 2003 Jan;61(2):113-20 [12622449.001]
  • [Cites] Neurol India. 2002 Mar;50(1):75-80 [11960157.001]
  • [Cites] J Neurooncol. 2009 Apr;92(2):211-7 [19050994.001]
  • [Cites] J Neurosurg Pediatr. 2008 Sep;2(3):215-21 [18759606.001]
  • [Cites] Am J Pathol. 1993 Nov;143(5):1294-300 [8238248.001]
  • [Cites] Neth J Med. 2007 Apr;65(4):132-6 [17452761.001]
  • [Cites] J Neurosurg Spine. 2006 Jul;5(1):68-71 [16850960.001]
  • [Cites] N Engl J Med. 1994 Aug 4;331(5):294-9 [8022439.001]
  • [Cites] Neuroradiology. 1994 Apr;36(3):228-30 [8041447.001]
  • [Cites] Chin Med J (Engl). 2007 May 5;120(9):844-6 [17531131.001]
  • (PMID = 20697491.001).
  • [ISSN] 1998-3727
  • [Journal-full-title] Indian journal of orthopaedics
  • [ISO-abbreviation] Indian J Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2911938
  • [Keywords] NOTNLM ; Cauda equina syndrome / primitive neuro-ectodermal tumor / spinal tumor
  •  go-up   go-down


3. Cornec D, Devauchelle Pensec V, Joulin SJ, Saraux A: Dramatic efficacy of infliximab in cauda equina syndrome complicating ankylosing spondylitis. Arthritis Rheum; 2009 Jun;60(6):1657-60
Hazardous Substances Data Bank. Infliximab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dramatic efficacy of infliximab in cauda equina syndrome complicating ankylosing spondylitis.
  • Cauda equina syndrome is an uncommon complication of ankylosing spondylitis (AS) characterized by the slow and insidious development of severe neurologic impairment.
  • No medical or surgical treatment has been proven effective.
  • We managed the care of a 66-year-old man who had longstanding AS and clinical features of cauda equina syndrome, including anal incontinence and buttock hypoesthesia.
  • The patient was treated with infliximab, a monoclonal antibody to tumor necrosis factor alpha that is used for the treatment of active AS.
  • The treatment was continued, and he was still doing well 1 year later.
  • This is the first report of an effective treatment for cauda equina syndrome complicating AS.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antirheumatic Agents / therapeutic use. Polyradiculopathy / drug therapy. Polyradiculopathy / etiology. Spondylitis, Ankylosing / complications
  • [MeSH-minor] Aged. Humans. Infliximab. Magnetic Resonance Imaging. Male. Treatment Outcome. Tumor Necrosis Factor-alpha / antagonists & inhibitors

  • Genetic Alliance. consumer health - Ankylosing Spondylitis.
  • Genetic Alliance. consumer health - Spondylitis.
  • MedlinePlus Health Information. consumer health - Ankylosing Spondylitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arthritis Rheum. 2010 May;62(5):1559-60; author reply 1560-1 [20178129.001]
  • (PMID = 19479855.001).
  • [ISSN] 0004-3591
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antirheumatic Agents; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab
  •  go-up   go-down


Advertisement
4. Yone K, Ijiri K, Hayashi K, Yokouchi M, Takenouchi T, Manago K, Nerome Y, Ijichi O, Ikarimoto N, Komiya S: Primary malignant peripheral nerve sheath tumor of the cauda equina in a child case report. Spinal Cord; 2004 Mar;42(3):199-203
Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant peripheral nerve sheath tumor of the cauda equina in a child case report.
  • STUDY DESIGN: A case report of primary malignant peripheral nerve sheath tumor (MPNST) of the cauda equina in a child is presented, and the literature is reviewed.
  • OBJECTIVE: To discuss the problems involved in the treatment of primary intradural MPNSTs.
  • MRI revealed an intradural tumor at L3-L5 level.
  • Following laminectomy of L3, L4 and L5, the tumor was removed en bloc.
  • Based on pathological and immunohistological findings, the tumor was diagnosed as an MPNST.
  • RESULTS: Although adjuvant chemotherapy was administered local recurrence and cerebral and spinal metastases of the tumor were found 6 months after the operation.
  • Following additional incomplete removal of the recurrent tumor, radiation therapy was administered.
  • Although recurrent and metastatic tumors disappeared or diminished in size by radiation, tumors increased in size thereafter, despite additional adjuvant chemotherapy.
  • Although no gold standard for the treatment of tumors has been established yet, surgical removal of tumors combined with postoperative high-dose radiation may be recommended.
  • [MeSH-major] Cauda Equina / pathology. Nerve Sheath Neoplasms / pathology. Nerve Sheath Neoplasms / secondary. Peripheral Nervous System Neoplasms / pathology
  • [MeSH-minor] Brain Neoplasms / secondary. Child, Preschool. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Spinal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15001982.001).
  • [ISSN] 1362-4393
  • [Journal-full-title] Spinal cord
  • [ISO-abbreviation] Spinal Cord
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. Amin A, Saifuddin A, Flanagan A, Patterson D, Lehovsky J: Radiotherapy-induced malignant peripheral nerve sheath tumor of the cauda equina. Spine (Phila Pa 1976); 2004 Nov 1;29(21):E506-9
Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy-induced malignant peripheral nerve sheath tumor of the cauda equina.
  • OBJECTIVES: To report a rare case of radiation-induced malignant peripheral nerve sheath tumor of the cauda equina 10 years after treatment for testicular seminoma.
  • SUMMARY OF BACKGROUND DATA: Development of malignant peripheral nerve sheath tumor after irradiation is well recognized and often associated with a dismal prognosis.
  • There have been isolated reports of malignant peripheral nerve sheath tumor developing in sites of previous irradiation for testicular seminoma.
  • RESULTS: A 38-year-old man presented with signs of cauda equina syndrome.
  • Ten years previously, he had undergone right radical inguinal orchidectomy and adjuvant para-aortic radiotherapy as treatment for Stage I testicular seminoma.
  • Magnetic resonance imaging demonstrated an inoperable intra- and extradural tumor leading to significant cauda equina compression.
  • CT-guided biopsy revealed a diagnosis of malignant peripheral nerve sheath tumor, most likely due to previous radiotherapy.
  • His clinical condition did not improve, and he underwent a course of palliative chemotherapy.
  • The authors report the fourth case resulting from adjuvant radiotherapy for testicular seminoma, with the present report being the first report of extensive intradural tumor leading to cauda equina syndrome.
  • [MeSH-major] Cauda Equina. Neoplasms, Radiation-Induced / etiology. Nerve Sheath Neoplasms / etiology. Peripheral Nervous System Neoplasms / etiology. Radiotherapy, Adjuvant / adverse effects
  • [MeSH-minor] Accidental Falls. Adult. Antineoplastic Agents / therapeutic use. Cervical Intraepithelial Neoplasia. Humans. Male. Orchiectomy. Palliative Care. Polyradiculopathy / etiology. Postoperative Complications / etiology. Retrospective Studies. Sciatica / complications. Seminoma / radiotherapy. Seminoma / surgery. Testicular Neoplasms / radiotherapy. Testicular Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15507791.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 21
  •  go-up   go-down


6. Fabre E, Guillevin R, Chretien F, Le Guerinel C, Duffau H: Peripheral primitive neuroectodermal tumor of the cauda equina in an elderly patient. Case report. J Neurosurg Spine; 2006 Jul;5(1):68-71

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral primitive neuroectodermal tumor of the cauda equina in an elderly patient. Case report.
  • Primitive neuroectodermal tumors (PNETs) are aggressive neoplasms composed predominantly of undifferentiated cells that show evidence of neural differentiation.
  • The authors report the case of a 70-year-old man with no significant medical history, in whom a peripheral PNET was demonstrated that, based on clinical and imaging findings, manifested as a nonspecific intrathecal tumoral process arising from the cauda equina.
  • Although this lesion is rare in the elderly, the authors' case illustrates the importance of making this diagnosis as early as possible so that a treatment plan may be devised.
  • The use of chemotherapy in association with radiotherapy in relation to the resection of the tumor should be reconsidered.
  • [MeSH-major] Cauda Equina. Neuroectodermal Tumors, Primitive, Peripheral / diagnosis. Peripheral Nervous System Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16850960.001).
  • [ISSN] 1547-5654
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Kinoshita Y, Akatsuka K, Ohtake M, Kamitani H, Watanabe T: Primary intramedullary spinal cord germinoma. Neurol Med Chir (Tokyo); 2010;50(7):592-4
Genetic Alliance. consumer health - Germinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 21-year-old woman presented with an intramedullary spinal cord germinoma and a history of gait disturbance and elimination disorder.
  • Magnetic resonance (MR) imaging demonstrated two isolated lesions, one located within the medulla between T9 and T11, and another at the cauda equina (L2 to L3 levels).
  • After partial reduction of the intramedullary mass, histological findings revealed that the tumor was typical germinoma.
  • Combined chemotherapy (carboplatin and etoposide) and whole spine radiation were performed.
  • No recurrence of the tumor has been detected 3 years after the operation, and no dissemination into the cranial area was detected.
  • Cisplatin and etoposide chemotherapy combined with radiotherapy is recommended for primary spinal germinoma, and is effective for inhibition of both tumor dissemination and recurrence.
  • [MeSH-major] Germinoma / diagnosis. Germinoma / surgery. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Multiple Primary / surgery. Spinal Cord Neoplasms / diagnosis. Spinal Cord Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Lumbar Vertebrae. Radiotherapy, Adjuvant. Spinal Cord / pathology. Spinal Cord / surgery. Thoracic Vertebrae. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20671389.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Reyns N, Assaker R, Louis E, Lejeune JP: Leptomeningeal hemangioblastomatosis in a case of von Hippel-Lindau disease: case report. Neurosurgery; 2003 May;52(5):1212-5; discussion 1215-6
MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Seven years after the last operation, he developed chronic hydrocephalus.
  • Despite a ventriculoperitoneal shunt procedure, he experienced progressive worsening of gait disturbances, associated with touch numbness of the lower limbs and Parinaud's syndrome.
  • Magnetic resonance imaging of the brain and spine showed evidence of leptomeningeal contrast enhancement around the brainstem, spinal cord, and cauda equina and enlarged tortuous vessels around the mesencephalon.
  • It is assumed that the tumor arose in the pia mater and that its direction of growth was purely extramedullary, invading all subarachnoid spaces.
  • The patient had a poor outcome as a result of progressive tetraplegia and died 6 months after diagnosis as a result of respiratory failure.
  • This case report illustrates the crucial challenge to develop a specific drug therapy related to angiogenesis in von Hippel-Lindau disease.
  • [MeSH-major] Hemangioblastoma / etiology. Hemangioblastoma / pathology. Meningeal Neoplasms / etiology. Meningeal Neoplasms / pathology. von Hippel-Lindau Disease / complications. von Hippel-Lindau Disease / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12699568.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Bourezgui M, Rafai MA, El Moutawakkil B, Boulaajaj FZ, Sibai M, Lezar S, Adil A, Benchkroun S, Kadiri R, Slassi I: [Cauda equina syndrome revealing neuroblastoma]. Rev Neurol (Paris); 2008 Dec;164(12):1048-51
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cauda equina syndrome revealing neuroblastoma].
  • [Transliterated title] Syndrome de la queue de cheval révélant un neuroblastome.
  • INTRODUCTION: Neuroblastoma is the most common solid tumor of childhood.
  • CASE REPORT: A 7-year-old child was hospitalized for cauda equina syndrome.
  • Blood and urinary catecholamine level were elevated confirming the diagnosis of neuroblastoma.
  • She was treated with chemotherapy alone with partial neurological recovery.
  • DISCUSSION AND CONCLUSION: Cauda equina compression revealing neuroblastoma is exceptional especially at an early phase in the youngest patients.
  • Treatment is based on surgical resection and/or chemotherapy and/or radiation therapy.
  • [MeSH-major] Neuroblastoma / pathology. Polyradiculopathy / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Catecholamines / blood. Catecholamines / urine. Child. Female. Gadolinium. Humans. Magnetic Resonance Imaging. Spinal Cord / pathology

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18808776.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Catecholamines; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


10. Engelhard HH, Villano JL, Porter KR, Stewart AK, Barua M, Barker FG, Newton HB: Clinical presentation, histology, and treatment in 430 patients with primary tumors of the spinal cord, spinal meninges, or cauda equina. J Neurosurg Spine; 2010 Jul;13(1):67-77
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical presentation, histology, and treatment in 430 patients with primary tumors of the spinal cord, spinal meninges, or cauda equina.
  • OBJECT Patients having a primary tumor of the spinal cord, spinal meninges or cauda equina, are relatively rare.
  • Neurosurgeons encounter and treat such patients, and need to be aware of their clinical presentation, tumor types, treatment options, and potential complications.
  • METHODS Extensive information on individuals diagnosed (in the year 2000) as having a primary CNS neoplasm was prospectively collected in a Patient Care Evaluation Study conducted by the Commission on Cancer of the American College of Surgeons.
  • Intraspinal tumor cases were identified based on ICD-O-2 topography codes C70.1, C72.0, and C72.1.
  • RESULTS Patients with primary intraspinal tumors represented 4.5% of the CNS tumor group, and had a mean age of 49.3 years.
  • Pain was the most common presenting symptom, while the most common tumor types were meningioma (24.4%), ependymoma (23.7%), and schwannoma (21.2%).
  • Radiation therapy and chemotherapy were administered to 20.3% and 5.6% of patients, respectively.
  • [MeSH-major] Cauda Equina / pathology. Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Peripheral Nervous System Neoplasms / pathology. Peripheral Nervous System Neoplasms / surgery. Spinal Cord Neoplasms / pathology. Spinal Cord Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Chi-Square Distribution. Child. Child, Preschool. Ependymoma / epidemiology. Ependymoma / pathology. Ependymoma / surgery. Female. Humans. Infant. Male. Meningioma / epidemiology. Meningioma / pathology. Meningioma / surgery. Middle Aged. Neurilemmoma / epidemiology. Neurilemmoma / pathology. Neurilemmoma / surgery. Postoperative Complications / epidemiology. Prospective Studies. Radiotherapy, Adjuvant. Registries. Risk Factors. Treatment Outcome. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20594020.001).
  • [ISSN] 1547-5646
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Morita M, Osawa M, Naruse H, Nakamura H: Primary NK/T-cell lymphoma of the cauda equina: a case report and literature review. Spine (Phila Pa 1976); 2009 Nov 15;34(24):E882-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary NK/T-cell lymphoma of the cauda equina: a case report and literature review.
  • OBJECTIVE: To describe an unusual case of primary lymphoma of the cauda equina and provide a review of the literature of this condition.
  • SUMMARY OF BACKGROUND DATA: Primary lymphoma of the cauda equina is extremely rare, and has been reported in 8 cases previously.
  • This report is the first to describe a case of primary nasal type NK/T-cell lymphoma of the cauda equina.
  • METHODS: We report the case of a 67-year-old man presenting the symptoms of cauda equina syndrome caused by primary lymphoma of the cauda equina.
  • RESULTS: After laminectomy and removal of the tumor, the patient recovered from the symptoms of cauda equina syndrome except for bladder and bowel dysfunction.
  • Further investigations including immunohistochemical stains made a diagnosis of primary nasal type NK/T-cell lymphoma of the cauda equina, and the patient received radiotherapy to the lumbosacral area.
  • Brain metastasis was detected 8 months after surgery, and the patient died 14 months after his initial clinical presentation despite additional treatments including whole-brain radiotherapy and oral chemotherapy.
  • CONCLUSION: Although primary lymphoma of the cauda equina is extremely rare, the prognosis of this condition is thought to be poor.
  • Early definitive diagnosis with examination of the cerebrospinal fluid followed by combined treatment with radiotherapy and high-dose methotrexate should be considered.
  • [MeSH-major] Lumbar Vertebrae / pathology. Lymphoma, Extranodal NK-T-Cell / pathology. Polyradiculopathy / pathology. Spinal Canal / pathology. Spinal Cord Neoplasms / pathology. Spinal Nerve Roots / pathology
  • [MeSH-minor] Aged. Brain Neoplasms / secondary. Decompression, Surgical. Fatal Outcome. Humans. Laminectomy. Magnetic Resonance Imaging. Male. Myelography. Neoplasm Metastasis / pathology. Neoplasm Metastasis / physiopathology. Radiotherapy. Sciatica / etiology. Treatment Outcome. Urinary Bladder, Neurogenic / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19910757.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


12. Epstein NE, Drexler S, Schneider J: Clear cell meningioma of the cauda equina in an adult: case report and literature review. J Spinal Disord Tech; 2005 Dec;18(6):539-43
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell meningioma of the cauda equina in an adult: case report and literature review.
  • Tumors recur in up to 40% of cases within 15 postoperative months and are often managed with repeated resection with or without radiation therapy.
  • The management strategy for adults with clear cell meningiomas involving the lumbar spinal canal (cauda equina) is less clearly defined.
  • An L2-L5 laminectomy was performed for gross total excision of the intradural lesion, which was adherent to one nerve root of the cauda equina.
  • Frozen-section diagnosis confirmed clear cell tumor.
  • Negative postoperative chest, abdominal, and pelvic computed tomography studies ruled out tumor of renal cell origin.
  • Consultations with multiple oncologists and radiation therapists recommended neither radiation nor chemotherapy following this initial surgery.
  • The high recurrence rate for clear cell meningiomas in children requires repeated tumor resection with or without secondary radiation therapy.
  • Following gross total resection of lumbar tumors in adults, reserving radiation therapy for secondary recurrences provides optimal management.
  • [MeSH-major] Cauda Equina / pathology. Cauda Equina / surgery. Meningioma / diagnosis. Meningioma / surgery. Peripheral Nervous System Neoplasms / diagnosis. Peripheral Nervous System Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Paresis / diagnosis. Paresis / etiology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16306847.001).
  • [ISSN] 1536-0652
  • [Journal-full-title] Journal of spinal disorders & techniques
  • [ISO-abbreviation] J Spinal Disord Tech
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 10
  •  go-up   go-down


13. Kotil K, Kilinc BM, Bilge T: Spinal metastasis of occult lung carcinoma causing cauda equina syndrome. J Clin Neurosci; 2007 Apr;14(4):372-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal metastasis of occult lung carcinoma causing cauda equina syndrome.
  • Cauda equina syndrome (CES) may be caused by tumor, herniated disc, trauma and spinal infections.
  • A 50-year-old man presented with a subacute CES caused by an intradural metastasis of an adenocarcinoma of the lung to the lumbosacral cauda fibers.
  • The operative findings were also suggestive of neurinoma with involvement of three nerve roots, and a well-demarcated tumor without infiltration into the subarachnoid space.
  • Although the findings of the operation were suggestive of neurinoma, final pathological diagnosis revealed metastatic carcinoma.
  • Chest X-ray and high resolution contrasted pulmonary computed tomography were normal.
  • Positron emission tomography (PET) showed a lung mass, at the left apex.
  • The patient was treated with chemotherapy and post-operative spinal radiotherapy was also performed.
  • MRI of intradural cauda equina metastasis may be similar to that of intradural nerve sheath tumor.
  • Surgery and postoperative radiotherapy may be effective for the treatment of CES due to lung carcinoma.
  • Definitive diagnosis is by histopathological examination with immunohistochemistry.
  • [MeSH-major] Adenocarcinoma, Clear Cell / secondary. Lung Neoplasms / pathology. Peripheral Nervous System Neoplasms / secondary. Polyradiculopathy / etiology
  • [MeSH-minor] Humans. Male. Middle Aged. Positron-Emission Tomography. Spinal Cord Neoplasms / pathology. Spinal Cord Neoplasms / radiotherapy. Spinal Cord Neoplasms / secondary. Spinal Cord Neoplasms / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17336230.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


14. Tait MJ, Chelvarajah R, Garvan N, Bavetta S: Spontaneous hemorrhage of a spinal ependymoma: a rare cause of acute cauda equina syndrome: a case report. Spine (Phila Pa 1976); 2004 Nov 1;29(21):E502-5
Hazardous Substances Data Bank. WARFARIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous hemorrhage of a spinal ependymoma: a rare cause of acute cauda equina syndrome: a case report.
  • OBJECTIVES: To document a rare case of rapid neurologic deterioration as a consequence of spinal tumoral hemorrhage and to highlight important issues regarding tumor histologic subtype and the impact of anticoagulation that have emerged from an illuminating review of the literature.
  • SUMMARY OF BACKGROUND DATA: To our knowledge, there have been only 8 reported cases of hemorrhage from an ependymoma of the filum terminale or conus medullaris causing acute cauda equina syndrome.
  • METHODS: We report the case of a 57-year-old woman who developed nontraumatic acute cauda equina syndrome, including sphincter compromise.
  • CONCLUSIONS: The possibility of an underlying tumor should always be borne in mind so that adequate preoperative planning can be undertaken.
  • [MeSH-major] Cauda Equina. Ependymoma / complications. Hemorrhage / etiology. Polyradiculopathy / etiology. Spinal Neoplasms / complications
  • [MeSH-minor] Anticoagulants / adverse effects. Anticoagulants / therapeutic use. Atrial Fibrillation / complications. Female. Hematoma / etiology. Humans. Laminectomy. Magnetic Resonance Imaging. Middle Aged. Mitral Valve Stenosis / complications. Rheumatic Heart Disease / complications. Rupture, Spontaneous. Thrombophilia / drug therapy. Thrombophilia / etiology. Warfarin / adverse effects. Warfarin / therapeutic use

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15507790.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 5Q7ZVV76EI / Warfarin
  • [Number-of-references] 20
  •  go-up   go-down


15. Fassett DR, Schmidt MH: Lumbosacral ependymomas: a review of the management of intradural and extradural tumors. Neurosurg Focus; 2003 Nov 15;15(5):E13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the lumbosacral region, ependymomas are most commonly associated with the conus medullaris and cauda equina, but can also occur extradurally in the sacrum, presacral tissues, or subcutaneous tissues over the sacrum.
  • These two tumor locations produce different management concerns.
  • For both tumors, it appears that gross-total resection is the treatment of choice when feasible.
  • The role of radiation therapy has not been adequately studied for either tumor location, but most clinicians use this modality in patients with subtotal resection of intradural ependymomas, local recurrence, or CNS dissemination.
  • Data supporting the use of radiation therapy for extradural ependymomas are lacking.
  • There does not appear to be a significant role for chemotherapy in either tumor location.
  • Much depends on extradural tumor location, however; the outlook is better for dorsal sacral tumors than presacral tumors.
  • [MeSH-major] Ependymoma / surgery. Lumbar Vertebrae / surgery. Sacrum / surgery. Spinal Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Biopsy. Central Nervous System Neoplasms / secondary. Child. Combined Modality Therapy. Diagnostic Imaging. Dura Mater. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15323470.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 38
  •  go-up   go-down


16. Olmarker K, Rydevik B: Selective inhibition of tumor necrosis factor-alpha prevents nucleus pulposus-induced thrombus formation, intraneural edema, and reduction of nerve conduction velocity: possible implications for future pharmacologic treatment strategies of sciatica. Spine (Phila Pa 1976); 2001 Apr 15;26(8):863-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective inhibition of tumor necrosis factor-alpha prevents nucleus pulposus-induced thrombus formation, intraneural edema, and reduction of nerve conduction velocity: possible implications for future pharmacologic treatment strategies of sciatica.
  • STUDY DESIGN: The possibility to prevent nucleus pulposus-induced functional and structural nerve root injury by selective tumor necrosis factor-alpha inhibition was assessed in an experimental model in the pig spine.
  • OBJECTIVE: The objective of the study was to evaluate the role of tumor necrosis factor-alpha in the mediation of nucleus pulposus-induced nerve injury by using selective inhibition.
  • SUMMARY OF BACKGROUND DATA: The cytokine tumor necrosis factor-alpha has been suggested to play a key role in the nerve root injury induced by local application of nucleus pulposus.
  • However, previous studies have not been able to distinguish the effects between tumor necrosis factor-alpha and other disc-related cytokines because of the use of nonspecific cytokine inhibition.
  • METHODS: Autologous nucleus pulposus was harvested from a lumbar disc and applied to the porcine sacrococcygeal cauda equina.
  • The pigs were simultaneously treated with two selective tumor necrosis factor-alpha inhibitors (etanercept n = 8 and infliximab n = 5), a heparin analogue (enoxaparin n = 5) or saline for control (n = 5).
  • RESULTS: The two tumor necrosis factor-alpha inhibitors prevented the reduction of nerve conduction velocity and also seemed to limit the nerve fiber injury, the intracapillary thrombus formation, and the intraneural edema formation.
  • However, treatment with enoxaparin did not seem to be different from control regarding reduction of nerve conduction velocity or histologic changes.
  • CONCLUSIONS: The data clearly indicate that tumor necrosis factor-alpha is involved in the basic pathophysiologic events leading to nerve root structural and functional changes after local application of nucleus pulposus.
  • The study therefore provides a basic scientific platform with potential clinical implications regarding the use of anti-tumor necrosis factor-alpha medication as treatment in patients with disc herniation and sciatica.
  • [MeSH-major] Edema / prevention & control. Intervertebral Disc / pathology. Intervertebral Disc Displacement / complications. Sciatica / drug therapy. Thrombosis / prevention & control. Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • [MeSH-minor] Animals. Antibodies, Monoclonal / pharmacology. Anticoagulants / pharmacology. Antirheumatic Agents / pharmacology. Cauda Equina / pathology. Cauda Equina / physiopathology. Enoxaparin / pharmacology. Etanercept. Immunoglobulin G / pharmacology. Infliximab. Nerve Fibers / pathology. Nerve Fibers / physiology. Neural Conduction / drug effects. Receptors, Tumor Necrosis Factor. Spinal Nerve Roots / pathology. Spinal Nerve Roots / physiopathology. Swine

  • MedlinePlus Health Information. consumer health - Blood Clots.
  • MedlinePlus Health Information. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Herniated Disk.
  • MedlinePlus Health Information. consumer health - Sciatica.
  • Hazardous Substances Data Bank. Infliximab .
  • Hazardous Substances Data Bank. Etanercept .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11317106.001).
  • [ISSN] 0362-2436
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Anticoagulants; 0 / Antirheumatic Agents; 0 / Enoxaparin; 0 / Immunoglobulin G; 0 / Receptors, Tumor Necrosis Factor; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab; OP401G7OJC / Etanercept
  •  go-up   go-down


17. Arnold PM, Habib A, Newell K, Anderson KK: Esthesioneuroblastoma metastatic to the thoracic intradural and extradural space. Spine J; 2009 May;9(5):e1-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND CONTEXT: Ethesioneuroblastoma (ENB) is a rare tumor of the olfactory epithelium that has been shown to metastasize mostly to the cervical lymphatics, with only infrequent spread to other locations.
  • Computed tomography of the chest showed no pulmonary metastasis and a high-attenuation spinal canal mass at T8 was noted on magnetic resonance imaging.
  • A tumor was seen penetrating through the dura, and a midline durotomy was performed for resection of a large intradural mass.
  • RESULTS: The postoperative period was uneventful, and included pain management and physical therapy, followed by chemotherapy and radiation.
  • CONCLUSIONS: Metastasis of ENB to the spinal column is rare, and of those instances, 80% are localized to the cauda equina.
  • [MeSH-major] Epidural Space / pathology. Esthesioneuroblastoma, Olfactory / secondary. Nasal Cavity / pathology. Nose Neoplasms / pathology. Spinal Cord Neoplasms / secondary
  • [MeSH-minor] Dura Mater / pathology. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Thoracic Vertebrae

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18805062.001).
  • [ISSN] 1878-1632
  • [Journal-full-title] The spine journal : official journal of the North American Spine Society
  • [ISO-abbreviation] Spine J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Mori R, Sakai H, Kato M, Hida T, Nakajima M, Fukuda T, Fukunaga M, Abe T: [Olfactory neuroblastoma with spinal metastasis: case report]. No Shinkei Geka; 2007 May;35(5):503-8
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Olfactory neuroblastoma is a rare tumor of the nasal cavity.
  • It is a locally aggressive tumor with local recurrence, and distant metastasis occurs in 22-40% of patients.
  • We report a case of olfactory neuroblastoma with cauda equina metastases.
  • He complained of lumbago in autumn, 2005 and MRI showed two enhanced lesions in the cauda equina.
  • Whole-spine irradiation of 32 Gy and lumber-spine irradiation of 10 Gy were performed.
  • Olfactory neuroblastoma is a radiosensitive tumor, and radiotherapy for spinal metastasis was reported to be effective.
  • However, effectiveness of chemotherapy was still uncertain.
  • Radiotherapy and further treatment including chemotherapy should be considered in case of spinal metastasis.
  • [MeSH-major] Cauda Equina. Esthesioneuroblastoma, Olfactory / secondary. Esthesioneuroblastoma, Olfactory / surgery. Nasal Cavity. Nose Neoplasms / pathology. Nose Neoplasms / surgery. Peripheral Nervous System Neoplasms / secondary

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17491347.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Olcay L, Aribaş BK, Gökçe M: A patient with acute myeloblastic leukemia who presented with conus medullaris syndrome and review of the literature. J Pediatr Hematol Oncol; 2009 Jun;31(6):440-7
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lumbosacral magnetic resonance imaging revealed clumped and thickened cauda equina nerve roots, epidural and periradicular diffuse soft tissue, which was enhanced with gadolinium.
  • Chemotherapy and local radiotherapy for both the face and the spine, yielded bone marrow remission and abatement in neurologic and radiologic findings, but he developed bone marrow relapse and died because of sepsis.
  • [MeSH-minor] Antigens, CD / metabolism. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Child. Combined Modality Therapy. Face / pathology. Flow Cytometry. Humans. Magnetic Resonance Imaging. Male. Radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19648794.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor
  • [Number-of-references] 34
  •  go-up   go-down


20. Massengo S, Riffaud L, Morandi X, Bernard M, Verin M: Nervous system lymphoid infiltration in Waldenström's macroglobulinemia. A case report. J Neurooncol; 2003 May;62(3):353-8
MedlinePlus Health Information. consumer health - Peripheral Nerve Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • She did not receive any specific treatment for Wm owing to a lack of symptoms.
  • This infiltration was located in the lower perimedullary and cauda equina roots regions, with possible centromedullary involvement.
  • General and intrathecal chemotherapy led to clinical, biological and radiological improvement over a four-year period.
  • [MeSH-minor] Acute Disease. Aged. Female. Humans. Lymphocytes, Tumor-Infiltrating / pathology. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Haematol. 1993;90(4):206-8 [8140863.001]
  • [Cites] Helv Med Acta. 1958 May;25(2):153-83 [13548797.001]
  • [Cites] Neurochirurgie. 1997;43(4):245-9 [9686227.001]
  • [Cites] Neurology. 1961 Mar;11:239-45 [13725698.001]
  • [Cites] Ann Med Interne (Paris). 1985;136(2):121-4 [3935023.001]
  • [Cites] Br J Haematol. 1999 Jul;106(1):100-3 [10444169.001]
  • [Cites] Acta Med Scand. 1961 Jun;169:691-9 [13680876.001]
  • [Cites] Arch Neurol. 1960 Nov;3:564-73 [13763183.001]
  • [Cites] Hematol Oncol Clin North Am. 1999 Dec;13(6):1351-66 [10626154.001]
  • [Cites] Acta Med Scand. 1950;138(1):1-14 [15432135.001]
  • [Cites] Schweiz Med Wochenschr. 1957 Oct 2;87(39-40):1243-6 [13485998.001]
  • [Cites] Schweiz Arch Neurol Neurochir Psychiatr. 1975;116(1):59-82 [807967.001]
  • [Cites] Hematol Oncol Clin North Am. 1992 Apr;6(2):347-58 [1582977.001]
  • [Cites] Am J Hematol. 2002 Feb;69(2):127-31 [11835349.001]
  • [Cites] J Clin Oncol. 1995 Sep;13(9):2476 [7666113.001]
  • (PMID = 12777090.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Hayakawa H, Obama K, Tara M: [Intradural recurrence of multiple myeloma during the hematological complete remission]. Rinsho Ketsueki; 2002 Nov;43(11):1009-13
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pretreatment examination revealed IgG-lambda type M-protein, Bence-Jones protein and the posterior mediastinum tumor.
  • As a result of VAD, MP, interferon and radiation therapy, he had a hematological complete remission.
  • After 21 months, he developed intradural relapse at cauda equina and cerebrum.
  • Many plasma cells and IgG-lambda type M-protein were detected in the cerebrospinal fluid.
  • The myeloma cells might have infiltrated the intradural space at diagnosis and expanded in the central nervous system despite chemotherapy.
  • Because reported cases with cerebral and meningeal myeloma are increasing according to the recent advance of treatment, we must pay attention to the meningeal myeloma.
  • [MeSH-major] Brain Neoplasms / etiology. Cauda Equina. Multiple Myeloma / etiology. Peripheral Nervous System Neoplasms / etiology

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12508488.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 14
  •  go-up   go-down


22. Stefan DC, Van Toorn R, Andronikou S: Spinal compression due to Burkitt lymphoma in a newly diagnosed HIV-infected child. J Pediatr Hematol Oncol; 2009 Apr;31(4):252-5
MedlinePlus Health Information. consumer health - HIV/AIDS.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a newly diagnosed HIV-infected child, without prior history of AIDS-defining disease, who presented with Burkitt lymphoma-related cauda equina syndrome that rapidly progressed to a flaccid paraplegia.
  • Diagnosis was confirmed on biopsy and magnetic resonance imaging of the spine showed multiple epidural masses with involvement of several vertebral bodies, cord edema and compression of the cord and cauda equina.
  • Chemotherapy (LMB 89 modified protocol) was initiated immediately after histopathologic confirmation, together with highly active antiretroviral therapy.
  • The outcome of the case highlights the importance of early diagnosis and prompt treatment of this aggressive tumor to avoid permanent neurologic deficits.
  • [MeSH-major] Burkitt Lymphoma / complications. HIV Infections / complications. Polyradiculopathy / etiology. Spinal Cord Compression / etiology. Spinal Cord Neoplasms / complications

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19346875.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Mostafavi H, Lennarson PJ, Traynelis VC: Granulocytic sarcoma of the spine. Neurosurgery; 2000 Jan;46(1):78-83; discussion 83-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Spinal complications of chloromas, such as cord compression secondary to epidural tumor or cauda equina syndrome, have been described but are uncommon.
  • Treatment strategies included surgery, chemotherapy, and radiotherapy.
  • Six patients received chemotherapy, and six patients received radiotherapy at doses of 2000 to 3000 cGy in up to 30 fractions.
  • RESULTS: Patient survival ranged from 18 days to 9.5 years after diagnosis.
  • A review of the previously reported cases of granulocytic sarcoma in addition to our new cases reveals that the most effective treatment is multimodality therapy coupled with early diagnosis.
  • CONCLUSION: Increased awareness of this entity will facilitate early diagnosis and minimize potentially preventable neurological morbidity.
  • [MeSH-major] Leukemia, Myeloid / diagnosis. Spinal Cord Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10626938.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 41
  •  go-up   go-down


24. Collini P, Mezzelani A, Modena P, Dagrada P, Tamborini E, Luksch R, Gronchi A, Navarria P, Sozzi G, Pilotti S: Evidence of neural differentiation in a case of post-therapy primitive neuroectodermal tumor/Ewing sarcoma of bone. Am J Surg Pathol; 2003 Aug;27(8):1161-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence of neural differentiation in a case of post-therapy primitive neuroectodermal tumor/Ewing sarcoma of bone.
  • Neural differentiation with the appearance of ganglion-like cells has been reported in untreated primitive neuroectodermal tumor/Ewing sarcoma (PNET/EWS) at peculiar sites, such as the cauda equina, and following treatment.
  • The case is presented here of a 17-year-old girl with a tumor in the iliac bone.
  • The tumor had the typical morphology of this tumor type and showed diffuse membranous immunoreactivity for CD99, intense immunoreactivity for synaptophysin, and focal immunoreactivity for neuron-specific enolase and S-100 protein.
  • The patient underwent chemotherapy and radiotherapy, followed by right internal hemipelvectomy.
  • The post-treatment residual viable tumor showed a morphologic appearance resembling a neuroblastoma, with immunoreactivity for NB84a, Hu, synaptophysin, and chromogranins A and B, but not for CD99.
  • RT-PCR performed on tumor tissue before and after therapy showed the presence of the EWS-FLI1 fusion transcript, type I in both samples.
  • This case of PNET/EWS is unique in the sense of showing the typical fusion transcript associated with this tumor both in the morphologically typical pretherapy tumor and in the sample from the post-therapy specimen showing neuroblastoma-like features.
  • [MeSH-major] Bone Neoplasms / pathology. Neuroectodermal Tumors, Primitive / pathology. Sarcoma, Ewing / pathology
  • [MeSH-minor] Adolescent. Biomarkers, Tumor. Cell Transformation, Neoplastic. Disease-Free Survival. Female. Humans. Ilium / pathology. Ilium / radiography. Neoplasms, Second Primary. Neuroblastoma / genetics. Neuroblastoma / pathology. Neuroblastoma / therapy. Oncogene Proteins, Fusion / genetics. Oncogene Proteins, Fusion / metabolism. Proto-Oncogene Protein c-fli-1. RNA, Messenger / metabolism. RNA, Neoplasm / analysis. RNA-Binding Protein EWS. Reverse Transcriptase Polymerase Chain Reaction. Transcription Factors / genetics. Transcription Factors / metabolism

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12883251.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / EWS-FLI fusion protein; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Protein c-fli-1; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / RNA-Binding Protein EWS; 0 / Transcription Factors
  •  go-up   go-down


25. Ohno T, Sakamoto T, Mizumoto C, Miyoshi T, Ueda M, Takeoka T, Yamashita K, Hishita T, Hada S: Leukemic and meningeal relapse of CD5+ intravascular large B-cell lymphoma with down-modulation of CD20 after rituximab therapy. Int J Hematol; 2006 Jul;84(1):74-8
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemic and meningeal relapse of CD5+ intravascular large B-cell lymphoma with down-modulation of CD20 after rituximab therapy.
  • Although CD20- relapses of B-cell lymphoma following rituximab therapy have increasingly been reported recently, coexistence of both the original and selected clones on relapse in a single patient have not been described.
  • A 46-year-old woman was admitted because of IVL complicated with cauda equina syndrome and pulmonary infarction.
  • Complete remission was successfully achieved with multidrug chemotherapy in combination with rituximab.
  • However, CD20 expression was decreased remarkably compared with that in the CSF and that in the bone marrow before therapy.
  • The targeting of CD20 molecules on the tumor cell surface by rituximab may have provided a selective pressure on lymphoma cells.
  • [MeSH-major] Antigens, CD20. Antigens, CD5. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, B-Cell / prevention & control. Meningeal Neoplasms / prevention & control. Tumor Escape / drug effects
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Female. Gene Expression Regulation, Leukemic / drug effects. Humans. Lymphocytes / metabolism. Lymphocytes / pathology. Middle Aged. Recurrence. Remission Induction. Rituximab

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1998 May 15;82(10):1963-72 [9587131.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):60-6 [12517778.001]
  • [Cites] Br J Haematol. 2000 Dec;111(3):826-34 [11122144.001]
  • [Cites] Blood. 2002 Feb 1;99(3):815-21 [11806981.001]
  • [Cites] Leuk Lymphoma. 2002 Dec;43(12):2335-41 [12613521.001]
  • [Cites] Mayo Clin Proc. 1996 Sep;71(9):869-73 [8790264.001]
  • [Cites] Ann Oncol. 1998 Sep;9(9):995-1001 [9818074.001]
  • [Cites] Ann Oncol. 2002 Jun;13(6):928-43 [12123339.001]
  • [Cites] Hum Pathol. 2000 Feb;31(2):220-6 [10685637.001]
  • [Cites] Int J Hematol. 2003 Feb;77(2):159-63 [12627851.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2573-9 [7989931.001]
  • [Cites] Cancer. 1993 May 15;71(10):3156-64 [8490846.001]
  • [Cites] J Pathol. 1993 Mar;169(3):291-5 [8492220.001]
  • [Cites] Leuk Lymphoma. 2003 Jun;44(6):1043-7 [12854907.001]
  • [Cites] Leuk Lymphoma. 2001 Aug;42(4):731-8 [11697503.001]
  • [Cites] Crit Rev Oncol Hematol. 2001 Oct;40(1):3-16 [11578912.001]
  • [Cites] Int J Hematol. 2003 Apr;77(3):286-94 [12731674.001]
  • [Cites] Semin Diagn Pathol. 1991 May;8(2):91-101 [1871454.001]
  • [Cites] Br J Haematol. 2002 Nov;119(2):412-6 [12406079.001]
  • (PMID = 16867907.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antigens, CD5; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


26. Mizutani J, Fukuoka M, Tsubouchi S, Otsuka T, Tono Y, Shimizu S, Matsui N: A rare case of lumbosacral meningioma: nondural attachment and possible enlargement by orally administered sex steroid. Spine (Phila Pa 1976); 2002 Aug 15;27(16):E377-81
Hazardous Substances Data Bank. MESTRANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • She had undergone oral sex steroid therapy for long-term oligomenorrhea.
  • Radiography disclosed a lumbosacral intradural tumor.
  • RESULTS: Complete removal of the tumor was performed.
  • The tumor was not adherent to the dura, and its appearance was that of a typical neurilemmoma.
  • However, the pathologic diagnosis was meningioma.
  • CONCLUSIONS: The tumor in the reported case may have enlarged in response to orally ingested sex steroid pills.
  • The gross appearance of the tumor during surgery was typical of neurilemmoma.
  • All the cases reported so far, including the current case, have involved tumor located in the lumbosacral region.
  • [MeSH-major] Dura Mater / pathology. Gonadal Steroid Hormones / adverse effects. Meningioma / chemically induced. Meningioma / diagnosis. Spinal Cord Neoplasms / chemically induced. Spinal Cord Neoplasms / diagnosis
  • [MeSH-minor] Administration, Oral. Adult. Cauda Equina / pathology. Cauda Equina / radiography. Cauda Equina / surgery. Chlormadinone Acetate / administration & dosage. Chlormadinone Acetate / adverse effects. Diagnosis, Differential. Female. Humans. Hypesthesia / etiology. Low Back Pain / etiology. Lumbosacral Region. Magnetic Resonance Imaging. Mestranol / administration & dosage. Mestranol / adverse effects. Myelography. Neurilemmoma / diagnosis. Oligomenorrhea / drug therapy. Spine / pathology. Spine / radiography. Spine / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHLORMADINONE ACETATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12195080.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gonadal Steroid Hormones; 0SY050L61N / Chlormadinone Acetate; B2V233XGE7 / Mestranol
  •  go-up   go-down






Advertisement